Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Launay O, et al. PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725. PLoS One. 2007. PMID: 17712402 Free PMC article. Clinical Trial.
Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
Pialoux G, Hocini H, Pérusat S, Silberman B, Salmon-Ceron D, Slama L, Journot V, Mathieu E, Gaillard C, Petitprez K, Launay O, Chêne G; ANRS VAC14 Study Group. Pialoux G, et al. Among authors: launay o. Vaccine. 2008 May 19;26(21):2657-66. doi: 10.1016/j.vaccine.2007.11.002. Epub 2007 Nov 26. Vaccine. 2008. PMID: 18068876 Clinical Trial.
Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study.
Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, Girard PM, Bélarbi L, Guérin C, Dimet J, Williams V, Krivine A, Salmon D, Lortholary O, Rey D; HEPAVAC Study Group1. Launay O, et al. J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):272-5. doi: 10.1097/QAI.0b013e318183a9c0. J Acquir Immune Defic Syndr. 2008. PMID: 18845961 Clinical Trial.
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML. Launay O, et al. Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9. Vaccine. 2009. PMID: 19135496 Clinical Trial.
[Vaccination in patients with cirrhosis].
Loulergue P, Launay O; le groupe GEVACCIM (Groupe d'Etude sur la Vaccination des Sujets Immunodéprimés). Loulergue P, et al. Among authors: launay o. Presse Med. 2009 Jul-Aug;38(7-8):1134-40. doi: 10.1016/j.lpm.2008.11.015. Epub 2009 Jan 29. Presse Med. 2009. PMID: 19185447 Review. French.
Why actively promote vaccination in patients with cirrhosis?
Loulergue P, Pol S, Mallet V, Sogni P, Launay O; GEVACCIM Group. Loulergue P, et al. Among authors: launay o. J Clin Virol. 2009 Nov;46(3):206-9. doi: 10.1016/j.jcv.2009.05.006. Epub 2009 Jun 4. J Clin Virol. 2009. PMID: 19501019 Review.
497 results